Literature DB >> 15726504

Chemotherapy for advanced colorectal cancer: let's not forget how we got here (until we really can).

Bert H O'Neil1, Richard M Goldberg.   

Abstract

Physicians and patients alike have been heartened by the recent advances in the treatment of colorectal cancer. The emergence of novel agents that are active in the treatment of this devastating disease, such as cetuximab and bevacizumab, has been particularly notable. However, even before these recent events, a substantial change in prognosis for patients with metastatic colorectal cancer had occurred as a result of advances in traditional chemotherapeutic agents. Refinements in dose, schedule, and sequence continue to be made that could lead to further improvements in outcomes. Additionally, new chemotherapeutic agents with promise for activity in colorectal cancer are being studied. Chemotherapy is likely to remain a central element of the treatment strategy. Our understanding of its current role is discussed in this article.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15726504     DOI: 10.1053/j.seminoncol.2004.09.030

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  2 in total

1.  Colorectal cancer: Irinotecan therapy-following a trail of breadcrumbs?

Authors:  Richard M Goldberg; Bert H O'Neil
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-09       Impact factor: 46.802

2.  Schedule-dependent activity of 5-fluorouracil and irinotecan combination in the treatment of human colorectal cancer: in vitro evidence and a phase I dose-escalating clinical trial.

Authors:  C Barone; M Landriscina; M Quirino; M Basso; C Pozzo; G Schinzari; G Di Leonardo; E D'Argento; N Trigila; A Cassano
Journal:  Br J Cancer       Date:  2006-12-12       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.